Quanta Therapeutics to Present First Clinical Data for Novel KRAS G12D Inhibitor QTX3034 at Major Cancer Conference
核心洞察
Quanta Therapeutics (搜索) will present Phase 1 clinical data for QTX3034, an oral G12D-preferring multi-KRAS (搜索) inhibitor, at the 2025 AACR-NCI-EORTC International Conference on October 24, 2025.
The ongoing Phase 1 trial evaluates QTX3034 as monotherapy and in combination with cetuximab in patients with KRASG12D (搜索) mutant solid tumors (搜索).
Dose expansion cohorts are enrolling patients with KRASG12D (搜索)-mutant pancreatic, colorectal, and endometrial cancers to assess safety, tolerability, and preliminary efficacy.
Quanta Therapeutics (搜索), a privately-held clinical-stage biopharmaceutical company, will present the first clinical data for its investigational KRAS (搜索) inhibitor QTX3034 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 24, 2025. The presentation marks a significant milestone for the oral G12D-preferring multi-KRAS inhibitor currently being evaluated in a Phase 1 clinical trial.
Clinical Trial Design and Endpoints
The ongoing Phase 1 clinical trial is evaluating QTX3034 in patients with solid tumors (搜索) harboring KRASG12D (搜索) mutations. The study employs a dual approach with dose escalation cohorts examining QTX3034 as both monotherapy and in combination with cetuximab, an established EGFR (搜索) inhibitor.
Dose expansion cohorts are actively enrolling patients with KRASG12D (搜索)-mutant pancreatic, colorectal, and endometrial cancers. The Phase 1 clinical endpoints encompass safety and tolerability assessment, determination of the maximum tolerated dose and recommended Phase 2 dose, pharmacokinetic properties evaluation, antitumor activity measurement, and molecular marker analysis.
Conference Presentation Details
Dr. Ignacio Garrido-Laguna from the Huntsman Cancer Institute at the University of Utah will present the clinical data during the "Spotlight on Proffered Papers 2: Clinical Advances in Targeting KRAS (搜索)" session. The presentation, titled "A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors (搜索) with KRASG12D (搜索) mutation," is scheduled for Friday, October 24, 2025, from 11:45 am to 12:15 pm in Level 3, Ballroom AB.
The data will also be featured in a poster presentation during Poster Session B from 12:30 to 4:00 p.m. ET in Level 2, Exhibit Hall D on the same day.
Innovative Drug Discovery Platform
Quanta Therapeutics (搜索) distinguishes itself through its unique high-throughput platform that applies Second Harmonic Generation (SHG) optical technology to identify allosteric modulators of protein complexes. This innovative approach enables the company to selectively target protein-protein interactions that are key to oncogenic RAS activity, addressing what the company describes as "the most prevalent and elusive target in oncology."
The company's vision centers on developing novel small molecule cancer medicines that can overcome the resistance paradigms commonly encountered in targeted oncology therapy. By applying innovative medicinal chemistry combined with its proprietary protein conformation detection technology, Quanta aims to advance differentiated, next-generation RAS programs.
Expanding KRAS Pipeline
Beyond QTX3034, Quanta's KRAS (搜索) inhibitor pipeline includes QTX3544, a multi-KRAS inhibitor with G12V-preferring activity currently in a Phase 1 clinical trial as monotherapy and in combination treatments for patients with KRASG12V (搜索)-driven solid tumors (搜索).
The clinical trial for QTX3034 (NCT06227377) is being conducted at clinical sites across the United States. Quanta Therapeutics (搜索) maintains headquarters in South San Francisco, California, with an additional site in Radnor, Pennsylvania.